top of page
Clinical trial title:
A Phase 1 Protocol to Study Intravenous TROCEPT-01 (ATTR-01) in Adult Participants with Select Epithelial Solid Tumours (ATTEST)
Background and study aim:
ATTEST is a Phase 1 trial which is testing a new drug called TROCEPT-01 (ATTR-01) to find out if it may work to treat different types of solid cancer.
How Trocept works - Home
What is TROCEPT-01 (ATTR-01)?
TROCEPT-01 (ATTR-01) is a new type of cancer drug designed to activate the immune system to attack and kill cancer cells. Thus, TROCEPT-01 (ATTR-01) is a type of immunotherapy. TROCEPT-01 (ATTR-01) has been engineered to only activate in cancer cells. TROCEPT-01 (ATTR-01) works by making a drug inside the cancer called a checkpoint inhibitor. Checkpoint inhibitors are approved cancer drugs that activate the immune system to attack and kill cancer cells.
However, current checkpoint inhibitors are given in the blood in active form where they can activate the immune system in healthy tissues, leading to exhaustion of T cell and toxicity in peripheral organs. In TROCEPT-01 (ATTR-01), because the checkpoint inhibitor will only be activated in the tumour, TROCEPT-01 (ATTR-01) has the potential be safer and more effective than current generation checkpoint inhibitors.
Pipeline
Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads.
Contact us if you’d like to discuss partnerships or collaborations.
bottom of page